We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hologic (HOLX) Flat As Market Sinks: What You Should Know
Read MoreHide Full Article
Hologic (HOLX - Free Report) closed at $72.68 in the latest trading session, marking no change from the prior day. The stock outperformed the S&P 500, which registered a daily loss of 0.04%. Elsewhere, the Dow gained 0.07%, while the tech-heavy Nasdaq lost 0.05%.
Heading into today, shares of the medical device maker had lost 8.51% over the past month, lagging the Medical sector's loss of 4.31% and the S&P 500's gain of 1.05% in that time.
The investment community will be paying close attention to the earnings performance of Hologic in its upcoming release. The company is forecasted to report an EPS of $1.01, showcasing a 3.06% upward movement from the corresponding quarter of the prior year. In the meantime, our current consensus estimate forecasts the revenue to be $1.03 billion, indicating a 1.39% growth compared to the corresponding quarter of the prior year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $4.29 per share and a revenue of $4.17 billion, signifying shifts of +5.15% and +3.53%, respectively, from the last year.
Investors should also take note of any recent adjustments to analyst estimates for Hologic. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, there's been a 0.2% rise in the Zacks Consensus EPS estimate. Right now, Hologic possesses a Zacks Rank of #3 (Hold).
Digging into valuation, Hologic currently has a Forward P/E ratio of 16.96. This expresses a discount compared to the average Forward P/E of 28.57 of its industry.
Also, we should mention that HOLX has a PEG ratio of 2.47. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As the market closed yesterday, the Medical - Instruments industry was having an average PEG ratio of 2.46.
The Medical - Instruments industry is part of the Medical sector. With its current Zacks Industry Rank of 53, this industry ranks in the top 22% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Hologic (HOLX) Flat As Market Sinks: What You Should Know
Hologic (HOLX - Free Report) closed at $72.68 in the latest trading session, marking no change from the prior day. The stock outperformed the S&P 500, which registered a daily loss of 0.04%. Elsewhere, the Dow gained 0.07%, while the tech-heavy Nasdaq lost 0.05%.
Heading into today, shares of the medical device maker had lost 8.51% over the past month, lagging the Medical sector's loss of 4.31% and the S&P 500's gain of 1.05% in that time.
The investment community will be paying close attention to the earnings performance of Hologic in its upcoming release. The company is forecasted to report an EPS of $1.01, showcasing a 3.06% upward movement from the corresponding quarter of the prior year. In the meantime, our current consensus estimate forecasts the revenue to be $1.03 billion, indicating a 1.39% growth compared to the corresponding quarter of the prior year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $4.29 per share and a revenue of $4.17 billion, signifying shifts of +5.15% and +3.53%, respectively, from the last year.
Investors should also take note of any recent adjustments to analyst estimates for Hologic. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, there's been a 0.2% rise in the Zacks Consensus EPS estimate. Right now, Hologic possesses a Zacks Rank of #3 (Hold).
Digging into valuation, Hologic currently has a Forward P/E ratio of 16.96. This expresses a discount compared to the average Forward P/E of 28.57 of its industry.
Also, we should mention that HOLX has a PEG ratio of 2.47. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As the market closed yesterday, the Medical - Instruments industry was having an average PEG ratio of 2.46.
The Medical - Instruments industry is part of the Medical sector. With its current Zacks Industry Rank of 53, this industry ranks in the top 22% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.